02697 真健康醫療－Ｂ
TH MEDICAL-B
TH MEDICAL-B
| Register Close | 2026/06/25 IPO Closing in 3 Days |
| Listing Date | 2026/06/30 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Guangdong True Health Medical Technology Development Co. was founded in 2018, it engages in developing and commercializing percutaneous puncture and ablation surgical robots in China. The Group has one Core Product, a percutaneous puncture surgical robot available in four models, namely, TH-S1, TH-S, TH-S Pro and TH-SA., all of which hold NMPA Class III registration certificates for lung and abdominal puncture and it is expanding the indication of TH-S1 to include retroperitoneal lesions.
--
The Group’s pipeline also includes two key products, the percutaneous microwave ablation surgical robot TH-X MW approved for the treatment of liver and lung tumors and the percutaneous microwave ablation surgical robot TH-X HMW approved for the treatment of liver tumors, and five additional product candidates, including the TH-P series of compact percutaneous puncture surgical robots which are approved for lung and abdominal puncture, the MW150 microwave ablation device, the TH-X Cryo cryoablation robot, the TH-LS KI300 and TH-LS LU100 ex vivo organ preservation and assessment systems.
--
According to the report, the Group ranked first in China in terms of revenue for percutaneous puncture surgical robots in 2025, with a 28% market share. As of June 14, 2026, the Group had one major manufacturing base located in Zhuhai, and had received marketing approval for 10 of its products (excluding disposables) and had built a customer base spanning 23 key provinces in China, primarily consisting of domestic distributors.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 20 |
GLOBAL OFFERING
| No. of Offer Shares | 3.56M H shares |
| No. of International Offer Shares | 3.21M H shares |
| No. of HK Offer Shares | 0.36M H shares |
| Offer Price | $119.30 - $135.40 |
| Stock Code | 2697 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited, DBS Asia Capital Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, DBS Asia Capital Limited, ABCI Securities Company Limited, Funde Securities Limited, CMBC Securities Company Limited, Livermore Holdings Limited, Open Securities Limited, South China Securities Limited, SPDB International Capital Limited |
TIME TABLE
| Application Period | Jun 22 (Mon) - noon, Jun 25 (Thu) |
| Price Determination Date | Jun 26 (Fri) |
| Result Announcement Date | On or before Jun 29 (Mon) |
| Result Announcement Date | On or before Jun 29 (Mon) |
| Result Announcement Date | On or before Jun 30 (Tue) |
| Dealings in Shares commence on | Jun 30, 2026. (Tue) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $119.30 - $135.40 |
| Capitalization (H Shares) | 4.25B - 4.83B |
| NAV / share ($) | $18.35 - $19.87 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 127.4, the net proceeds raised would be HKD 388.10M, of which |
| 74.5% : Research and development activities and commercialization of Core Product |
| 9.9% : Research and development activities and commercialization of key products |
| 6% : Research and development activities of other product candidates and related patent filings and portfolio expansion |
| 2% : Expansion of manufacturing capacity and enhance production capability |
| 7.6% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).